Although the patient’s epilepsy was effectively controlled, cognitive recovery was suboptimal, and anti-CV2/CRMP5 antibodies remained detectable even after clinical improvement, a finding consistent with previous literature (11). The gene discussed is DPYSL5; the disease is epilepsy.